TransMedics Group, Inc. (TMDX) saw its stock surge 5.22% in the intraday session on Tuesday, following the company's impressive fourth-quarter 2024 financial results and optimistic guidance for the current year.
The medical technology company reported strong revenue growth for Q4 2024, with revenue reaching $122 million, representing a significant increase from the previous year. Additionally, TransMedics recorded a notable jump in net income, climbing to nearly $7 million, a remarkable turnaround from the net loss reported in the prior year.
Investors were further buoyed by TransMedics' positive revenue guidance for 2025, with the company anticipating a 20% to 25% increase in revenue. This outlook likely fueled confidence in the company's growth prospects, driving the stock's substantial intraday gain.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。